Blog

  • Baroness Redfern – 2016 Parliamentary Question to the Department of Health

    Baroness Redfern – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Baroness Redfern on 2016-01-21.

    To ask Her Majesty’s Government what steps they are taking to increase awareness of different cancers and their symptoms through media sources, specifically radio, television, and internet advertising; and to encourage people with possible symptoms or concerns to visit their GP.

    Lord Prior of Brampton

    Public Health England (PHE) runs Be Clear on Cancer campaigns which are designed to raise the public’s awareness of specific cancer symptoms and encourage people with those symptoms to go to the doctor and diagnose cancer at an earlier stage.

    Be Clear on Cancer campaigns are tested at a local and regional level and are subject to a comprehensive evaluation process, the results of which are assessed thoroughly before a decision is taken on whether to run campaigns nationally throughout England.

    The campaigns run across a range of the media. Television advertising is commonly used as it is shown to be the best way to reach the target audience of people over the age of 50. Radio, press and outdoor advertising are used as supplementary channels, where appropriate for the audience. PHE has recently begun to advertise online, with a particular focus on social media such as Facebook, as audiences are increasingly using these services.

    PHE works closely with the Department and NHS England to ensure that healthcare professionals are also targeted with campaign information to encourage earlier diagnoses and referrals.

    To date, there have been national campaigns on Lung, Bowel, Bladder and Kidney, Oesophago-gastric cancers and Breast Cancer in older women. The next Be Clear on Cancer campaign will be “Blood in Pee” as a symptom of bladder and kidney cancers.

  • Baroness Redfern – 2016 Parliamentary Question to the Department for Environment, Food and Rural Affairs

    Baroness Redfern – 2016 Parliamentary Question to the Department for Environment, Food and Rural Affairs

    The below Parliamentary question was asked by Baroness Redfern on 2016-01-21.

    To ask Her Majesty’s Government what steps they are taking to ensure that departments assist projects such as the British Coatings Federation’s PaintCare project.

    Lord Gardiner of Kimble

    The Government welcomes the PaintCare initiative and is working constructively with the British Coating Federation in relation to several aspects of the project. This includes identifying potential regulatory barriers to the recycling and re-manufacturing of paint and how these might be overcome, as well as providing opportunities to raise awareness of the potential benefits of PaintCare, for example at the G7 Alliance for Resource Efficiency conference in Berlin last October.

    My Hon. Friend the Parliamentary Under Secretary (Department for Environment, Food and Rural Affairs), spoke at the Parliamentary launch of PaintCare’s interim report in November. The Waste and Resources Action Programme has also been working with PaintCare to provide information to consumers on how to recycle and dispose of household paint, through the Recycle Now campaign.

  • Baroness Redfern – 2016 Parliamentary Question to the Department for Business, Innovation and Skills

    Baroness Redfern – 2016 Parliamentary Question to the Department for Business, Innovation and Skills

    The below Parliamentary question was asked by Baroness Redfern on 2016-01-21.

    To ask Her Majesty’s Government what steps they are taking to encourage innovation in paint products to make better use of resources, and what steps they are taking to reduce the amount of waste going to landfill and to create new markets for paint products.

    Baroness Neville-Rolfe

    I am pleased to highlight a project by Akzo Nobel, Newlife Paints and Seymour Consulting supported through our delivery arm – Innovate UK – to industrialise the process of recycling paint through increased automation which has proved successful and could lead to significant commercial opportunities as well as a better environmental outcome.

    Additionally, the Government’s Innovation in Waste Prevention Fund is supporting a RePaint project in Cheshire which is working across the local community to minimise the amount of paint going for disposal.

    The disposal of liquid waste, including liquid paint, to landfill is banned under the Landfill Directive (Directive 1999/31/EC on the landfill of waste). The ban is implemented in England through the Environmental Permitting (England and Wales) Regulations 2010 (as amended) and is enforced by the Environment Agency through the environmental permits it issues to landfill operators.

    The creation of new markets for paint products was one of the recommendations from the British Coatings Federation’s “Paintcare” initiative which was launched last year. The Waste and Resources Action Programme (WRAP) is taking steps to encourage consumers to recycle/reuse household paint by providing information through the Recycle Now campaign. This includes a postcode locator to pinpoint local facilities and information on how to deal with paint.

  • Baroness Redfern – 2016 Parliamentary Question to the The Lord Chairman of Committees

    Baroness Redfern – 2016 Parliamentary Question to the The Lord Chairman of Committees

    The below Parliamentary question was asked by Baroness Redfern on 2016-01-21.

    To ask the Chairman of Committees what assessment he has made of the case for creating a circular economy for leftover paint in Parliament, in the light of the recommendations made in the British Coatings Federation’s interim report published on 19 November 2015.

    Lord Laming

    No formal assessment has been made of the Report. The House keeps minimal base colours in stock for touch-ups etc. and orders specific quantities as job requirements dictate. Any leftover paint is dealt with in compliance with legal disposal requirements.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government what are the costs per test in rare disease treatment using (1) whole genome, (2) whole exome, and (3) medical exome, sequencing; and if those figures are not available, why not.

    Lord Prior of Brampton

    This information is not held centrally by NHS England or the UK Genetic Testing Network. Where the cost of these tests falls outside of tariff, costs will vary according to commissioning arrangements, the systems in place and the technology used.

    The cost of whole genome sequencing will continue to change in line with advances in technology. Costs will also need to be defined and include full bioinformatics analysis and clinical interpretation which is likely to be more costly than the sequencing itself.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government how many (1) definitive, and (2) actionable, diagnoses are made for every 1,000 genomes sequenced as part of the rare disease arm of 100,000 Genomes Project; and how many diagnoses they estimate would have been made if the Project were run using (1) whole, and (2) medical, exome technology; and if those estimates are not available, why not.

    Lord Prior of Brampton

    The 100,000 Genomes Project is not intended to provide definitive or actionable findings from whole genome sequencing. This is the responsibility of the National Health Service Genomic Medicine Centres based on interpretation reports provided by Genomics England. To date approximately 20 reports have been issued based on the initial interpretation of the pilot phase genome data. It is not possible to estimate the comparison between whole genome and exome methods for these patients. That is because the eligibility criteria for patients to be invited to participate in the 100,000 Genomes Project require that they remain undiagnosed after standard NHS diagnostic tests.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government how many successful tumour-normal genomes Genomics England has sequenced, interpreted and returned to patients to date; how long on average it has taken to return those results to patients; and how many cancer patients have died without receiving their results after supplying tumour samples to the 100,000 Genomes Project.

    Lord Prior of Brampton

    The information requested is not yet available. The 100,000 Genomes Project is a research project which is investigating the benefits of whole genome sequencing for patients with cancer and rare diseases. One of the objectives of the Project is to establish the evidence to inform future decisions on National Health Service testing.

    The cancer part of the 100,000 Genomes Project has only recently completed the pilot phase and is incorporating those lessons into routine recruitment of cancer patients. To date, 1,286 tumour and normal genomes have been sequenced and are being interpreted by Genomics England. The pilot phase has involved research participants who have given informed consent, including details about whether there will be feedback of results during the pilot phase. The pilot phase has proved invaluable in understanding the technical requirements for sample preparation and data collection which will be incorporated into the main phase of recruitment in early 2016. As this phase is just starting there is no data on the average turn-around-time or on patient survival.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government whether the cancer panel test used at the main NHS tertiary hospitals will provide the vast majority of clinically actionable information in a tumour genome, in the light of the NHS reimbursement environment for targeted therapies.

    Lord Prior of Brampton

    A range of cancer panel tests are undertaken by National Health Service trusts. Whether or not these tests capture the majority of clinically actionable information in the tumour genome will not be known until the outcomes from the cancer element of the 100,000 Genomes Project is known.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government what estimate they have made of how many cancer patients could receive a molecular test on Genomics England’s cancer sequencing budget for 2016 if Genomics England (1) continued to use whole genome sequencing on tumour and normal tissue pairs, and (2) switched to deep sequenced panel tests.

    Lord Prior of Brampton

    The information requested is not yet available. The 100,000 Genomes Project is a research project which is investigating the benefits of whole genome sequencing for patients with cancer and rare diseases. One of the objectives of the Project is to establish the evidence to inform future decisions on National Health Service testing.

    The cancer part of the 100,000 Genomes Project has only recently completed the pilot phase and is incorporating those lessons into routine recruitment of cancer patients. To date, 1,286 tumour and normal genomes have been sequenced and are being interpreted by Genomics England. The pilot phase has involved research participants who have given informed consent, including details about whether there will be feedback of results during the pilot phase. The pilot phase has proved invaluable in understanding the technical requirements for sample preparation and data collection which will be incorporated into the main phase of recruitment in early 2016. As this phase is just starting there is no data on the average turn-around-time or on patient survival.

  • Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    Lord Freyberg – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

    To ask Her Majesty’s Government what are the costs, rather than the tariff, of a cancer molecular profile using (1) a whole tumour-normal pair using Illumina technology at 70× tumour coverage, and (2) a deep sequenced next-generation sequencing panel test, as deployed in most major NHS teaching hospitals; and if those figures are not available, why not.

    Lord Prior of Brampton

    This information is not held centrally by NHS England. Where the cost of these tests falls outside of tariff, costs will vary according to commissioning arrangements, the systems in place and the technology used.

    Further information on the costs to the National Health Service of whole genome sequencing in cancer and rare diseases will be derived through the 100,000 Genomes Project. The intended NHS re-procurement of Regional Genetic Laboratories will aid in defining the costs of genomic tests.